Drugs / TP53-EphA-2-CAR-DC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05631886 | Jul 2023 → Dec 2025 overdue | cancer, lymphoma | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TP53-EphA-2-CAR-DC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05631886 ↗ |
| Modality | Cell therapy | “autologous CAR-DC vaccine engineered with anti-EphA2 CAR and TP53 mutant peptide” NCT05631886 ↗ |
| Route | Intravenous | “administered by intravenous injection.” NCT05631886 ↗ |
| Target | EPHA2 | “scFv domain targeting EphA2 antigen” NCT05631886 ↗ |